HAEi Global Access Program2019-05-11T07:47:15+02:00

HAEi GLOBAL ACCESS PROGRAM

Thousands of patients suffering from HAE will have access to medicines for the first time, with the launch of the HAEi Global Access Program, a landmark medication access program.

HAEi is proud to announce the HAEi Global Access Program (HAEi GAP).

It is the first time that a patient group has initiated this type of medication distribution program.

The HAEi GAP model initially includes a ‘Named Patient Program’ where governments/hospitals order the medicine and provide reimbursement. Later it is also planned to include a ‘Compassionate Use Program’ that offers donated medication to patients in parts of the world where this type of program is allowed, and an ‘Early Access Program’ where access to medication will be given in conjunction with a phase III clinical trial.

The first pharmaceutical company in HAEi GAP is Pharming Group.

HAEi GAP enables patients in all countries where Ruconest is not commercially available to gain access to the drug through an ethical and regulatory compliant “Named Patient Program” mechanism.

Simultaneously HAEi is working with other pharmaceutical companies to include other medicines in the program as well.

HAEi GAP is run in partnership with the medicines access company Inceptua.

HAEi Global Access Program – click to download flyer

“The HAEi Global Access Program brings the opportunity of access to HAE medications in countries where modern therapies are otherwise unavailable. This is the first program of its kind in HAE, and we believe the first time this type of program has been initiated by a patient organization.”

Henrik Balle Boysen, Executive Vice President & Chief Operating Officer, HAEi

“HAEi is committed to securing access to HAE medications for patients across the globe. We are extremely proud to have established HAEi GAP with our current partners and will continue to work with other manufacturers with the hope of expanding the program in the future.”

Anthony J. Castaldo, President & Chief Executive Officer, HAEi

Currently available medicines through the HAEi Global Access Program

Ruconest®

Brand of recombinant C1-inhibitor (conestat alpha). Ruconest® is approved by FDA and EMA and is delivered intravenously. Ruconest® is approved for self-administration by FDA.

Company: Pharming Group NV

More information

HAE related topics that might interest you

Global Access Program

Helping to change the lives of patients with hereditary angioedema (HAE) with a medication access program

Global Perspectives

Magazine with timely information on the issues, activities, and events that are relevant to the global HAE community

HAEi Connect Member database

Free, secure online membership database and communications platform for HAEi’s member organizations

Regional Patient Advocates

Constantly strive to improve the situation for HAE friends all over the world – no matter how they are organized

Stay tuned – sign up for our newsletter

BE THE FIRST TO KNOW ABOUT HAE NEWS, TREATMENTS, EVENTS AND RELATED TOPICS

Click here to sign up

HAE Global Conference 2018

This 4th HAE conference was record breaking: A total of 736 patients and care givers participated from no less than 57 countries

HAEi hosted websites

Hosting of your national website or help for you to create a new website – naturally all in your native language